AbD Serotec and Spinreact Sign Supply Agreement for Antibodies used in Clinical Diagnostic Kits
News Jul 16, 2009
MorphoSys AG has announced that its research and diagnostic antibody segment AbD Serotec and Spinreact S.A., a Spanish biotechnology company, have signed a supply agreement.
Initially, the agreement covers the use of two antibodies which Spinreact will incorporate in a series of clinical diagnostic kits. AbD Serotec will continuously supply Spinreact with antibody material. Financial details of the agreement were not disclosed.
Dr Josep Puig, Chief Executive Officer of Spinreact, said "Spinreact is delighted to announce this agreement with AbD Serotec - an industry leader in providing tailored antibodies for research and diagnostic applications. The fast turn-around in antibody production offered by AbD Serotec, together with the high quality of the resulting antibodies, will help accelerate the process of development and validation, allowing Spinreact to bring new clinical diagnostic reagents for human diseases to the market in the shortest possible timeframe."
Chinese researchers have developed interfacially polymerized porous polymer particles for low- abundance glycopeptide separation. These polymer particles - with hydrophilic-hydrophobic heterostructured nanopores - can separate low-abundance glycopeptides from complex biological samples with high-abundance background molecules efficiently.